tiprankstipranks
Trending News
More News >
Brooks Laboratories Limited (IN:BROOKS)
:BROOKS
India Market
Advertisement

Brooks Laboratories Limited (BROOKS) AI Stock Analysis

Compare
1 Followers

Top Page

IN:BROOKS

Brooks Laboratories Limited

(BROOKS)

Rating:45Neutral
Price Target:
₹141.00
▼(-7.15% Downside)
Brooks Laboratories Limited's overall stock score is primarily impacted by its financial instability and overvaluation concerns. The company's negative cash flow and high P/E ratio are significant risks. Technical indicators suggest potential bearish momentum, but oversold conditions could lead to a short-term rebound.

Brooks Laboratories Limited (BROOKS) vs. iShares MSCI India ETF (INDA)

Brooks Laboratories Limited Business Overview & Revenue Model

Company DescriptionBrooks Laboratories Limited (BROOKS) is a pharmaceutical company based in India, primarily engaged in the manufacturing and marketing of a broad range of pharmaceutical products. The company specializes in the production of various formulations in the antibiotic, anti-diabetic, cardiovascular, and gastroenterology segments. Brooks Laboratories has established a presence in both domestic and international markets, focusing on delivering quality healthcare solutions.
How the Company Makes MoneyBrooks Laboratories Limited generates revenue through the sale of its pharmaceutical products, which include a wide range of formulations across different therapeutic segments. The company's primary revenue streams come from its domestic sales within India and exports to international markets. Brooks Laboratories also engages in contract manufacturing for other pharmaceutical companies, providing additional income. Strategic partnerships and collaborations with other pharmaceutical firms and research institutions further enhance its revenue capabilities by expanding its market reach and product offerings.

Brooks Laboratories Limited Financial Statement Overview

Summary
Brooks Laboratories Limited faces challenges with financial stability and profitability, as evidenced by negative net income and cash flow issues. Despite improvements in margins and debt management, revenue volatility and consistent positive cash flow are needed for better financial health.
Income Statement
45
Neutral
Brooks Laboratories Limited has shown inconsistent revenue growth, with a noticeable decline in revenue from 2022 to 2023, followed by a recovery in 2025. Gross profit margins have been volatile, indicating instability in cost management. However, the company has managed to improve its EBIT and EBITDA margins in 2025 compared to previous years, although net profit margins remain negative due to persistent net losses.
Balance Sheet
52
Neutral
The company's debt-to-equity ratio has improved as total debt decreased over recent years, suggesting better leverage management. The return on equity remains negative due to ongoing net losses, which is a concern. However, the equity ratio is relatively stable, indicating a strong equity position relative to total assets.
Cash Flow
40
Negative
Cash flow from operations has been negative for several years, but there has been some improvement in 2025. The company has struggled with free cash flow, indicating potential liquidity issues. The operating cash flow to net income ratio remains unfavorable due to sustained losses, although free cash flow has shown slight growth from a very low base.
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2022Dec 2020
Income Statement
Total Revenue948.95M825.57M632.05M790.12M900.93M691.33M
Gross Profit288.76M139.22M126.02M60.88M142.94M156.56M
EBITDA-73.45M58.22M-291.68M41.73M-134.50M-35.16M
Net Income-205.54M-99.67M-209.00M-195.92M-193.13M-243.76M
Balance Sheet
Total Assets0.001.24B1.10B904.45M1.96B1.58B
Cash, Cash Equivalents and Short-Term Investments8.08M12.48M13.78M1.25M23.85M3.96M
Total Debt0.0075.83M65.12M56.42M252.59M276.36M
Total Liabilities-592.09M255.90M356.44M248.60M615.91M594.48M
Stockholders Equity592.09M981.04M739.53M655.85M630.51M984.16M
Cash Flow
Free Cash Flow0.00-971.00K-149.58M-101.20M-650.53M-119.72M
Operating Cash Flow0.0017.62M-144.91M-96.81M-374.41M-93.89M
Investing Cash Flow0.00-460.41M4.95M1.82M-249.09M-23.26M
Financing Cash Flow0.00441.96M114.14M96.01M640.71M96.12M

Brooks Laboratories Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price151.85
Price Trends
50DMA
149.47
Positive
100DMA
142.47
Positive
200DMA
142.69
Positive
Market Momentum
MACD
-2.29
Positive
RSI
56.17
Neutral
STOCH
70.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Positive. The current price of 151.85 is above the 20-day moving average (MA) of 147.15, above the 50-day MA of 149.47, and above the 200-day MA of 142.69, indicating a bullish trend. The MACD of -2.29 indicates Positive momentum. The RSI at 56.17 is Neutral, neither overbought nor oversold. The STOCH value of 70.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BROOKS.

Brooks Laboratories Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
₹4.59B72.87
0.62%-9.14%-91.11%
62
Neutral
₹3.28B32.25
4.15%21.74%
54
Neutral
₹4.71B47.02
0.29%-9.90%33.18%
54
Neutral
₹3.65B38.50
-3.36%-47.58%
51
Neutral
$7.95B-0.40-41.67%2.21%22.29%-1.85%
45
Neutral
₹4.47B347.96
10.30%
43
Neutral
₹3.29B30.02
-3.41%-3028.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:BROOKS
Brooks Laboratories Limited
151.85
17.35
12.90%
IN:ALBERTDAVD
Albert David Ltd
803.65
-732.69
-47.69%
IN:MEDICAMEQ
Medicamen Biotech Limited
351.15
-77.37
-18.06%
IN:MEDICO
Medico Remedies Ltd.
39.22
-5.82
-12.92%
IN:NECLIFE
Nectar Lifesciences Ltd.
14.66
-37.03
-71.64%
IN:ZIMLAB
Zim Laboratories Ltd.
74.20
-45.50
-38.01%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 05, 2025